“…Fourth, our observation that D1 and D2 agonists have very similar effects that are the opposite of the effects of D1 and D2 antagonists has important implications for conclusions about the specificity of the drugs' effects. In most previous studies, microinjected D1 and D2 antagonists had very similar behavioral (Hiroi and White, 1991 ; Ozer et al, 1997 ; Koch et al, 2000 ; Yun et al, 2004b ; Eiler et al, 2006 ; Pezze et al, 2007 ; Lex and Hauber, 2008 ; Liao, 2008 ; Nicola, 2010 ; Shin et al, 2010 ; Haghparast et al, 2012 ; Steinberg et al, 2014 ) and electrophysiological (du Hoffmann and Nicola, 2014 ) effects. Because the concentration of injected antagonists required to observe effects is much higher than the binding constants of these drugs for their target receptors, the similarity of D1 and D2 antagonist effects calls into question their specificity: it is possible that the drugs either bind to the same dopamine receptor, or to a third receptor class that is not a dopamine receptor at all.…”